Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $277,000.

  • Caribou Biosciences' Cash from Financing Activities rose 13.52% to $277,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 64.00%. This contributed to the annual value of $16.7 million for FY2024, which is 89.16% down from last year.
  • Per Caribou Biosciences' latest filing, its Cash from Financing Activities stood at $277,000 for Q3 2025, which was up 4,516.67% from $6,000 recorded in Q2 2025.
  • Caribou Biosciences' Cash from Financing Activities' 5-year high stood at $322.7 million during Q3 2021, with a 5-year trough of -$43,000 in Q4 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $468,000 (2025), whereas its average is $15.6 million.
  • As far as peak fluctuations go, Caribou Biosciences' Cash from Financing Activities skyrocketed by 288,009.82% in 2021, and later crashed by 133.86% in 2023.
  • Caribou Biosciences' Cash from Financing Activities (Quarterly) stood at $460,000 in 2021, then crashed by 72.39% to $127,000 in 2022, then slumped by 133.86% to -$43,000 in 2023, then spiked by 9,083.72% to $3.9 million in 2024, then grew by 13.52% to $277,000 in 2025.
  • Its Cash from Financing Activities was $277,000 in Q3 2025, compared to $6,000 in Q2 2025 and $468,000 in Q1 2025.